02:25 PM EDT, 08/13/2025 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.)

ImmunityBio ( IBRX ) shares rose 15% in recent trading Wednesday after the company reported "promising" early results in the first two patients treated with a type of non-Hodgkins lymphoma using its CD19 CAR-NK natural killer cell therapy.

Findings from a phase I trial showed complete responses in the patients with late-stage Waldenstrom macroglobulinemia, the company said Wednesday in a statement.

The study is a first-in-human trial assessing the safety and preliminary efficacy of chemotherapy-free cell therapy and in combination with rituximab, the company said.

Price: 2.84, Change: +0.37, Percent Change: +14.77